STOCK TITAN

Charles River Laboratories International, Inc. - $CRL STOCK NEWS

Welcome to our dedicated page for Charles River Laboratories International news (Ticker: $CRL), a resource for investors and traders seeking the latest updates and insights on Charles River Laboratories International stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Charles River Laboratories International's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Charles River Laboratories International's position in the market.

Rhea-AI Summary

Charles River Laboratories reported first-quarter 2024 results with revenue of $1.01 billion, GAAP EPS of $1.30, and Non-GAAP EPS of $2.27. The company updated its 2024 guidance and reaffirmed revenue growth and non-GAAP earnings per share estimates. Despite revenue declines in the DSA segment, the RMS and Manufacturing segments showed growth. The company aims to capitalize on new business opportunities in the biopharmaceutical sector.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.21%
Tags
-
Rhea-AI Summary

Charles River Laboratories International, Inc. (NYSE: CRL) has launched viral vector reference materials to aid gene and cell therapy researchers, providing AAV and LVV products with high quality. The company aims to streamline the research and development process, offering superior serotypes and vector genome concentrations. The launch includes six AAV reference material serotypes and five LVV reference material products, contributing to their extensive CDMO offerings. The official launch will take place at the ASGCT Annual Meeting in May 2024, showcasing case study data and various presentations. Charles River's CGT portfolio and viral vector CDMO solutions aim to support client programs and assist in scaling from pre-clinical to commercial stages.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.2%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories (NYSE: CRL) has achieved 100% renewable electricity usage globally ahead of schedule, marking significant progress towards climate goals. The company joined RE100 in 2020 and committed to operating on 100% renewable electricity globally by 2030. Through virtual power purchase agreements in the US and Europe, Charles River now leads in sustainable energy practices.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.55%
Tags
none
Rhea-AI Summary
Charles River Laboratories launches Alternative Methods Advancement Project to reduce reliance on animal testing with a $500 million investment, focusing on innovation, partnerships, and advocacy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.52%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) is set to release its first-quarter 2024 financial results on May 9th, with a conference call scheduled for 8:30 a.m. ET. Investors can access the live webcast and replay on the Company's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) launches Patholytix Foresight, an AI decision support tool in collaboration with Deciphex. The tool enhances toxicologic pathology assessment, accelerates primary evaluation, and peer review in drug discovery. Patholytix Foresight streamlines workflows, improves efficiency, consistency, and accuracy in analyzing histopathology data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
AI
Rhea-AI Summary
Charles River Laboratories International, Inc. collaborates with Axovia Therapeutics to produce High Quality gene of interest plasmid to support gene therapy trials for Bardet-Biedl Syndrome. Axovia's lead program, AXV101, shows promising results in preclinical studies for BBS. The collaboration aims to develop transformative therapies for ciliopathies, a group of complex disorders affecting 1 in 1,000 people.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.87%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) partners with Ship of Theseus to manufacture GMP plasmid DNA for therapeutic use targeting various indications. Ship of Theseus focuses on HOX family biologics for tissue repair and maintenance. The collaboration aims to develop treatments for diabetic and chronic wounds, neutropenia, psoriasis, androgenetic alopecia, women’s health, infertility, and epithelial cancers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.34%
Tags
none
-
Rhea-AI Summary
Charles River Laboratories International, Inc. (NYSE: CRL) is showcasing new tools and services at the AACR Annual Meeting to support oncology research. The company is highlighting technology-driven capabilities, including the Apollo™ Price Estimator and the Cancer Model Database. Charles River will also present scientific posters and host a spotlight session on predictive tumor models and therapeutic antibody platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
none
Rhea-AI Summary
Charles River Laboratories International, Inc. (CRL) invests $200M in alternative testing methods and achieves 92% renewable energy usage worldwide, showcasing significant ESG progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.48%
Tags
none
Charles River Laboratories International, Inc.

NYSE:CRL

CRL Rankings

CRL Stock Data

11.19B
50.74M
0.98%
103.03%
3.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
WILMINGTON

About CRL

charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro